S&P 500   3,384.16 (+0.11%)
DOW   27,936.51 (-0.14%)
QQQ   274.27 (+0.89%)
AAPL   461.35 (+2.06%)
MSFT   210.71 (+0.73%)
FB   263.90 (+1.54%)
GOOGL   1,529.61 (+1.48%)
AMZN   3,207.98 (+1.45%)
NVDA   462.34 (+1.03%)
CGC   17.27 (+0.12%)
BABA   255.36 (+0.07%)
TSLA   1,639.00 (+5.42%)
GE   6.61 (-1.64%)
MU   46.79 (-3.49%)
AMD   82.50 (-0.13%)
T   29.97 (-0.70%)
F   7.10 (-0.14%)
ACB   10.00 (+2.04%)
GILD   68.06 (-1.13%)
NFLX   481.66 (+1.30%)
DIS   131.56 (-0.17%)
BAC   26.32 (-1.53%)
BA   176.56 (+0.64%)
S&P 500   3,384.16 (+0.11%)
DOW   27,936.51 (-0.14%)
QQQ   274.27 (+0.89%)
AAPL   461.35 (+2.06%)
MSFT   210.71 (+0.73%)
FB   263.90 (+1.54%)
GOOGL   1,529.61 (+1.48%)
AMZN   3,207.98 (+1.45%)
NVDA   462.34 (+1.03%)
CGC   17.27 (+0.12%)
BABA   255.36 (+0.07%)
TSLA   1,639.00 (+5.42%)
GE   6.61 (-1.64%)
MU   46.79 (-3.49%)
AMD   82.50 (-0.13%)
T   29.97 (-0.70%)
F   7.10 (-0.14%)
ACB   10.00 (+2.04%)
GILD   68.06 (-1.13%)
NFLX   481.66 (+1.30%)
DIS   131.56 (-0.17%)
BAC   26.32 (-1.53%)
BA   176.56 (+0.64%)
S&P 500   3,384.16 (+0.11%)
DOW   27,936.51 (-0.14%)
QQQ   274.27 (+0.89%)
AAPL   461.35 (+2.06%)
MSFT   210.71 (+0.73%)
FB   263.90 (+1.54%)
GOOGL   1,529.61 (+1.48%)
AMZN   3,207.98 (+1.45%)
NVDA   462.34 (+1.03%)
CGC   17.27 (+0.12%)
BABA   255.36 (+0.07%)
TSLA   1,639.00 (+5.42%)
GE   6.61 (-1.64%)
MU   46.79 (-3.49%)
AMD   82.50 (-0.13%)
T   29.97 (-0.70%)
F   7.10 (-0.14%)
ACB   10.00 (+2.04%)
GILD   68.06 (-1.13%)
NFLX   481.66 (+1.30%)
DIS   131.56 (-0.17%)
BAC   26.32 (-1.53%)
BA   176.56 (+0.64%)
S&P 500   3,384.16 (+0.11%)
DOW   27,936.51 (-0.14%)
QQQ   274.27 (+0.89%)
AAPL   461.35 (+2.06%)
MSFT   210.71 (+0.73%)
FB   263.90 (+1.54%)
GOOGL   1,529.61 (+1.48%)
AMZN   3,207.98 (+1.45%)
NVDA   462.34 (+1.03%)
CGC   17.27 (+0.12%)
BABA   255.36 (+0.07%)
TSLA   1,639.00 (+5.42%)
GE   6.61 (-1.64%)
MU   46.79 (-3.49%)
AMD   82.50 (-0.13%)
T   29.97 (-0.70%)
F   7.10 (-0.14%)
ACB   10.00 (+2.04%)
GILD   68.06 (-1.13%)
NFLX   481.66 (+1.30%)
DIS   131.56 (-0.17%)
BAC   26.32 (-1.53%)
BA   176.56 (+0.64%)
Log in

NASDAQ:NVCRNovocure Stock Price, Forecast & News

$76.40
+1.40 (+1.87 %)
(As of 08/13/2020 12:27 PM ET)
Add
Compare
Today's Range
$74.66
Now: $76.40
$76.79
50-Day Range
$57.20
MA: $66.08
$79.04
52-Week Range
$53.40
Now: $76.40
$98.84
Volume2,199 shs
Average Volume987,137 shs
Market Capitalization$7.72 billion
P/E Ratio636.72
Dividend YieldN/A
Beta1.62
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.72 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$76.40
+1.40 (+1.87 %)
(As of 08/13/2020 12:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock price been impacted by Coronavirus?

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVCR shares have increased by 13.2% and is now trading at $76.29.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novocure?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure
.

When is Novocure's next earnings date?

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Novocure
.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) released its earnings results on Thursday, July, 30th. The medical equipment provider reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.01. The medical equipment provider had revenue of $115.90 million for the quarter, compared to analysts' expectations of $105.96 million. Novocure had a net margin of 2.88% and a return on equity of 5.14%. Novocure's revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period last year, the company earned ($0.01) earnings per share.
View Novocure's earnings history
.

What price target have analysts set for NVCR?

8 brokers have issued 12 month price targets for Novocure's stock. Their forecasts range from $58.00 to $90.00. On average, they expect Novocure's stock price to reach $79.75 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Novocure
.

Has Novocure been receiving favorable news coverage?

Media headlines about NVCR stock have been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -4.1 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future.
View the latest news about Novocure
.

Are investors shorting Novocure?

Novocure saw a decline in short interest in June. As of June 30th, there was short interest totaling 3,380,000 shares, a decline of 17.0% from the June 15th total of 4,070,000 shares. Based on an average trading volume of 987,800 shares, the short-interest ratio is presently 3.4 days. Currently, 4.1% of the company's shares are sold short.
View Novocure's Short Interest
.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Who are Novocure's major shareholders?

Novocure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (0.93%), Rhenman & Partners Asset Management AB (0.37%), Goldman Sachs Group Inc. (0.37%), C WorldWide Group Holding A S (0.34%), Hartline Investment Corp (0.33%) and Bank of New York Mellon Corp (0.29%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti.
View institutional ownership trends for Novocure
.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Frontier Capital Management Co. LLC, Healthcare of Ontario Pension Plan Trust Fund, Nicholas Investment Partners LP, American International Group Inc., Bank of New York Mellon Corp, Goldman Sachs Group Inc., and First Trust Advisors LP. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure
.

Which major investors are buying Novocure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, Bullseye Asset Management LLC, Peregrine Capital Management LLC, Swiss National Bank, and Phoenix Holdings Ltd..
View insider buying and selling activity for Novocure
.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $76.29.

How big of a company is Novocure?

Novocure has a market capitalization of $7.71 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Novocure's official website?

The official website for Novocure is www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.